1. Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, Molyneux ME,
Marsh K, Taylor TE, Watkins WM, Winstanley PA: Chlorproguanildapsone
versus sulfadoxine-pyrimethamine for sequential
episodes of uncomplicated falciparum malaria in Kenya and
Malawi: a randomised clinical trial. Lancet 2002, 360:1136-1143.
2. Press Release on Lapdap [http://www.gsk.com/media/pressre
leases/2008/2008_pressrelease_0014.htm]
3. Assessment and monitoring of antimalarial drug efficacy for
the treatment of uncomplicated falciparum malaria [http://
www.who.int/malaria/docs/ProtocolWHO.pdf]
4. Lindegardh N, Annerberg A, Blessborn D, Bergqvist Y, Day N, White
NJ: Development and validation of a bioanalytical method
using automated solid-phase extraction and LC-UV for the
simultaneous determination of lumefantrine and its desbutyl
metabolite in plasma. J Pharm Biomed Anal 2005, 37:1081-1088.
5. Price RN, Uhlemann AC, van VM, Brockman A, Hutagalung R, Nair S,
Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten
F: Molecular and pharmacological determinants of the therapeutic
response to artemether-lumefantrine in multidrugresistant
Plasmodium falciparum malaria. Clin Infect Dis 2006,
42:1570-1577.
6. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian
J, Maldonado T, Duran D, Kaplan AH, Wenger NS: A comparison
study of multiple measures of adherence to HIV protease
inhibitors. Ann Intern Med 2001, 134:968-977.
7. World Malaria Report 2008 [http://www.who.int/malaria/
wmr2008/]
8. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB: The concordance
of self-report with other measures of medication
adherence: a summary of the literature. Med Care 2004,
42:649-652.
9. Bell DJ, Kapitao Y, Sikwese R, van Oosterhout JJ, Lalloo DG: Adherence
to antiretroviral therapy in patients receiving free
treatment from a government hospital in Blantyre, Malawi.
J Acquir Immune Defic Syndr 2007, 45:560-563.
10. Rahman MM, Dondorp AM, Day NP, Lindegardh N, Imwong M, Faiz
MA, Bangali AM, Kamal AT, Karim J, Kaewkungwal J, Singhasivanon P:
Adherence and efficacy of supervised versus non-supervised
treatment with artemether/lumefantrine for the treatment
of uncomplicated Plasmodium falciparum malaria in Bangladesh:
a randomised controlled trial. Trans R Soc Trop Med Hyg
2008, 102:861-867.
11. Ajayi IO, Browne EN, Bateganya F, Yar D, Happi C, Falade CO,
Gbotosho GO, Yusuf B, Boateng S, Mugittu K, Cousens S, Nanyunja
M, Pagnoni F: Effectiveness of artemisinin-based combination
therapy used in the context of home management of
malaria: a report from three study sites in sub-Saharan
Africa. Malar J 2008, 7:190.
12. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P,
Musabe J, Kyomugisha A, Guthmann JP: Adherence to a six-dose
regimen of artemether-lumefantrine for treatment of
uncomplicated Plasmodium falciparum malaria in Uganda.
Am J Trop Med Hyg 2004, 71:525-530.
13. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J: Simplified
antimalarial therapeutic monitoring: using the day-7 drug
level? Trends Parasitol 2008, 24:159-163.
14. Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC,
Kitcher ED, Badoe EV, Lamptey R, Goka BQ: Amodiaquineartesunate
vs artemether-lumefantrine for uncomplicated
malaria in Ghanaian children: a randomized efficacy and
safety trial with one year follow-up. Malar J 2008, 7:127.
15. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira
J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W,
Checchi F, Guthmann JP: Supervised versus unsupervised intake
of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara,
Uganda: a randomised trial. Lancet 2005, 365:1467-1473.
16. Sagara I, Diallo A, Kone M, Coulibaly M, Diawara SI, Guindo O, Maiga
H, Niambele MB, Sissoko M, Dicko A, Djimde A, Doumbo OK: A
randomized trial of artesunate-mefloquine versus artemether-
lumefantrine for treatment of uncomplicated Plasmodium
falciparum malaria in Mali. Am J Trop Med Hyg 2008,
79:655-661.
17. Urquhart J: Pharmacodynamics of variable patient compliance:
implications for pharmaceutical value. Adv Drug Deliv Rev
1998, 33:207-219.